Auritec Pharmaceuticals, Inc
www.auritecpharma.comAuritec Pharmaceuticals is an R&D company that specializes in innovative, sustained-release drug delivery systems. At Auritec, our focus is to leverage 20 years of experience from our scientific team in extended release delivery systems in a basic and applied research environment. Our early success in securing National Institute of Health (NIH) funding for much of this work is indicative of the level of expertise and the advanced state of Auritec's technology. In no other time in the history of pharmaceutical sciences has drug delivery played as many roles in bringing new therapies to patients as it is doing now. With the advent of combinatorial chemistry and high-throughput screening in drug discovery, the physicochemical properties of new drug candidates are such that the development of bioavailable dosage forms is becoming extremely difficult. There are also major cellular barriers to overcome in targeting drugs to their sites of action. Additionally, drugs discovered based on genomic and other biotechnological research are difficult to deliver to their sites of action in therapeutically beneficial and commercially viable forms. Drug delivery is also playing major roles in the life-cycle management of older products.
Read moreAuritec Pharmaceuticals is an R&D company that specializes in innovative, sustained-release drug delivery systems. At Auritec, our focus is to leverage 20 years of experience from our scientific team in extended release delivery systems in a basic and applied research environment. Our early success in securing National Institute of Health (NIH) funding for much of this work is indicative of the level of expertise and the advanced state of Auritec's technology. In no other time in the history of pharmaceutical sciences has drug delivery played as many roles in bringing new therapies to patients as it is doing now. With the advent of combinatorial chemistry and high-throughput screening in drug discovery, the physicochemical properties of new drug candidates are such that the development of bioavailable dosage forms is becoming extremely difficult. There are also major cellular barriers to overcome in targeting drugs to their sites of action. Additionally, drugs discovered based on genomic and other biotechnological research are difficult to deliver to their sites of action in therapeutically beneficial and commercially viable forms. Drug delivery is also playing major roles in the life-cycle management of older products.
Read moreCountry
State
California
City (Headquarters)
Santa Monica
Industry
Employees
11-50
Founded
2002
Estimated Revenue
$1,000,000 to $5,000,000
Social
Employees statistics
View all employeesPotential Decision Makers
Chief Operating Officer
Email ****** @****.comPhone (***) ****-****Laboratory Director
Email ****** @****.comPhone (***) ****-****Research Associate - Bioanalysis and Drug Delivery
Email ****** @****.comPhone (***) ****-****
Technologies
(3)